Jacqueline S. Garcia, MD

Jacqueline S. Garcia, MD, discusses the future expectations of trials and therapies to improve outcomes in myelofibrosis.

Jacqueline S. Garcia, MD, discusses the role of ruxolitinib (Jakafi) in myelofibrosis.

Jacqueline S. Garcia, MD, discusses the results of the phase 2 REFINE trial in patients with myelofibrosis.

Jacqueline S. Garcia, MD, discusses results from a phase II trial examining the addition of the BCL-2/BCL-XL inhibitor navitoclax to ruxolitinib in patients with primary or secondary myelofibrosis with acquired resistance to ruxolitinib.

Jacqueline S. Garcia, MD, discusses unmet needs for patients with myelofibrosis who progress on JAK inhibitors.

Jacqueline S. Garcia, MD, instructor in medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the management of thrombocytopenia with navitoclax in patients with myelofibrosis.

Jacqueline S. Garcia, MD, discusses the tolerability of the combination of navitoclax plus ruxolitinib in patients with myelofibrosis.

Jacqueline S. Garcia, MD,discusses how navitoclax differs from other agents in primary or secondary myelofibrosis.

Jacqueline S. Garcia, MD, instructor in Medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses research with the combination of navitoclax and ruxolitinib (Jakafi) in patients with myelofibrosis.